Verona Pharma plc (VRNA) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en London, United Kingdom. El CEO actual es David S. Zaccardelli.
VRNA tiene fecha de IPO 2017-04-28, 209 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $72.68B.
Verona Pharma plc is a clinical-stage biopharmaceutical company headquartered in London, focused on developing innovative therapies for respiratory diseases with significant unmet medical needs. The company's lead product candidate is ensifentrine, an inhaled dual inhibitor of phosphodiesterase 3 and 4 enzymes that functions as both a bronchodilator and anti-inflammatory agent in a single compound. Ensifentrine is currently in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis, with development proceeding across three delivery formulations: nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Founded in 2005, Verona Pharma is advancing a potentially transformative approach to respiratory disease management.
